Pine River Capital Management’s Myriad Genetics MYGN Stock Holding History

Pine River Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-5,484	Closed	-$206K	–	715
2015 Q3	$206K	Buy	+5,484	New	+$195K	﹤0.01%	599
2014 Q4	–	Sell	-77,099	Closed	-$2.97M	–	879
2014 Q3	$2.97M	Buy	+77,099	New	+$2.88M	0.03%	371

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Pine River Capital Management's MYGN Position: Q4 2015 in Review

Pine River Capital Management sold out of Myriad Genetics (MYGN) in Q4 2015, closing a stake of 5,484 shares — an estimated $206K sold.

Pine River Capital Management first reported a position in MYGN in Q3 2014 and held it in 2 quarters. The position peaked at $2.97M in Q3 2014. 232 funds tracked by Wall St. Rank hold MYGN as of Q4 2015.

Pine River Capital Management reported no remaining Myriad Genetics position as of Q4 2015 after selling out during the quarter.
Pine River Capital Management sold 5,484 Myriad Genetics shares in Q4 2015, an estimated $206K.
Pine River Capital Management first reported a position in Myriad Genetics in Q3 2014 and held it in 2 quarters.
Pine River Capital Management's Myriad Genetics position peaked at $2.97M in Q3 2014.
232 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2015.

Based on Pine River Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.